Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women ...

Short interest in Gilead Sciences Inc (NASDAQ:GILD) decreased during the last reporting period, falling from 22.34M to 21.39M. This put 1.72% of the company's publicly available shares short.

Intel, Core BTS, Salesforce, Verizon, ServiceNow, Cisco and Cyderes were among the tech companies making key executive hires ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and ...

Shares of Gilead Sciences Inc. GILD slid 4.57% to $107.25 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 5.97% to 5,074. ...

Investing.com - U.S. stocks opened mixed to lower on Wednesday, after the release of mixed first-quarter earnings reports and... Investing.com - U.S. stock futures pointed to a slightly lower open ...

In the latest market close, Gilead Sciences (GILD) reached $112.39, with a +0.45% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 4.84%.

Gilead Sciences (GILD) ended the recent trading session at $111.88, demonstrating a +0.54% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a ...

Headquartered in Foster City, CA, Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus (HIV). The company’s broad portfolio includes drugs for liver ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.